Does diethylstilbestrol (DES) cause elevation of serum SGPT (ALT) levels?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Does Diethylstilbestrol (DES) Cause SGPT (ALT) Elevation?

There is no evidence that diethylstilbestrol (DES) causes elevation of serum SGPT (ALT) levels. The available FDA drug labeling and medical literature do not identify hepatotoxicity or liver enzyme elevation as a known adverse effect of DES.

Evidence Review

FDA Drug Label

The FDA labeling for diethylstilbestrol 1 does not list hepatotoxicity, liver enzyme elevation, or ALT/SGPT elevation among its adverse effects or warnings. This is significant because drug-induced liver injury (DILI) serious enough to warrant clinical attention would be documented in official prescribing information.

Clinical Literature

A comprehensive review of DES health risks 2 identifies the major long-term complications associated with DES exposure:

  • Increased breast cancer risk
  • Cervical and vaginal clear cell adenocarcinoma
  • Reproductive tract abnormalities
  • Infertility and poor pregnancy outcomes
  • Early menopause

Notably absent from this list is any mention of hepatotoxicity or liver enzyme abnormalities.

Context from Other Cases

One case report 3 mentions a patient with "in utero exposure to diethylstilbestrol" who later developed acute liver injury, but this was clearly attributed to tyrosine kinase inhibitor (pazopanib) therapy for angiosarcoma—not to the historical DES exposure. The DES exposure was simply part of the patient's past medical history and was not implicated in the liver injury.

Clinical Implications

  • DES is not hepatotoxic: Unlike many hormonal agents and synthetic steroids that can cause liver enzyme elevation, DES does not appear to have this effect
  • If ALT is elevated in a patient with DES history: Look for alternative causes (alcohol, viral hepatitis, fatty liver disease, other medications, etc.)
  • Historical exposure only: Since DES was discontinued in the 1970s-1980s, any current patients would have been exposed decades ago, making it even less plausible as a cause of current liver enzyme abnormalities

Common Pitfall to Avoid

Do not attribute liver enzyme elevations to DES simply because it is a synthetic estrogen. While some hormonal therapies (particularly oral contraceptives and anabolic steroids) can cause hepatotoxicity 4, this is not a class effect of all estrogenic compounds. Each agent must be evaluated based on its specific pharmacologic profile and documented adverse effects.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.